Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem

QR Code

Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem

The article discusses the use of bioanalogues (BAs) in the treatment of rheumatoid arthritis using the example of the comparable efficacy, tolerability and immunogenicity of the original biologic disease-modifying antirheumatic drug (bDMARD) etanercept (ETC) and its BA GP-2015. We discuss the mainte...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. V. Chichasova, A. M. Lila
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2024-12-01
Series:	Современная ревматология
Subjects:	rheumatoid arthritis biologic disease-modifying antirheumatic drug etanercept biosimilar gp2015 nocebo
Online Access:	https://mrj.ima-press.net/mrj/article/view/1673
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases
by: A. E. Karateev, et al.
Published: (2022-12-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system
by: A. Yu Kulikov, et al.
Published: (2022-06-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Erelzi<sup>®</sup> – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel)
by: V. I. Mazurov, et al.
Published: (2021-08-01)

Peculiarities of pharmacotherapy of patients with rheumatoid arthritis associated with interstitial lung disease
by: A. V. Gordeev, et al.
Published: (2024-02-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Body composition and skeletal muscles status in patients with rheumatoid arthritis during treatment with biologic disease-modifying antirheumatic drugs
by: O. V. Dobrovolskaya, et al.
Published: (2025-02-01)

End-stage rheumatoid arthritis: specific features of patient management
by: Nadezhda Aleksandrovna Shostak, et al.
Published: (2013-06-01)

Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
by: A. O. Bobkova, et al.
Published: (2023-07-01)

Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational Study
by: Bessette L, et al.
Published: (2025-06-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

COVID-19 and post-covid syndrome in patients with rheumatoid arthritis
by: E. S. Aronova, et al.
Published: (2023-08-01)

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
by: V. N. Amirdzhanova, et al.
Published: (2014-09-01)

Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
by: A. E. Karateev, et al.
Published: (2022-09-01)

Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
by: A. O. Bobkova, et al.
Published: (2024-08-01)

The clinical and pathogenetic value of Foxp3+ T regulatory cells in rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2016-10-01)

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA
by: T. V. Popkova, et al.
Published: (2016-07-01)

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Efficacy and safety of the biosimilar etanercept in the treatment of patients with rheumatoid arthritis and spondyloarthritis
by: B. G. Issayeva, et al.
Published: (2024-10-01)

Baricitinib: key results of long-term use in rheumatoid arthritis
by: N. V. Chichasova, et al.
Published: (2024-08-01)

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)
by: E. L. Nasonov, et al.
Published: (2016-12-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
by: E. N. Koltsova, et al.
Published: (2022-12-01)

THE IMPACT OF ADEQUATE PSYCHOPHARMACOTHERAPY ON THE EFFICIENCY OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin, et al.
Published: (2018-05-01)

Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience
by: A. I. Zagrebneva, et al.
Published: (2022-12-01)

LONG-TERM SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OF MODERATE OR HIGH ACTIVITY (RESULTS OF PHASE III MULTICENTER EXTENSION CLINICAL STUDY ML28124)
by: E. L. Nasonov, et al.
Published: (2018-07-01)

Pharmacoeconomic study of active psoriatic arthritis treatment
by: A. V. Rudakova, et al.
Published: (2025-02-01)

Treatment strategy for rheumatoid arthritis: hot topics
by: D. E. Karateev
Published: (2015-03-01)

FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES
by: A. A. Abramkin, et al.
Published: (2018-09-01)

Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice
by: E. Yu. Loginova, et al.
Published: (2021-10-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2015-09-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2015-10-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2016-12-01)

CHANGES IN THE LEVEL OF FoxP3+ REGULATORY T LYMPHOCYTES IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS DURING METHOTREXATE THERAPY
by: A. S. Avdeeva, et al.
Published: (2017-09-01)

Safety and efficiency of therapy by gene-engineering-biological preparations of rheumatoid arthritis
by: E. A. Strel’tsov
Published: (2018-10-01)

Dynamics of global longitudinal strain of the left ventricular myocardium and blood biomarker levels in patients with rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs or Janus kinase inhibitors
by: Yu. N. Gorbunova, et al.
Published: (2023-10-01)

The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)
by: M. A. Korolev, et al.
Published: (2021-01-01)